MANCHESTER, England, June 12, 2013 /CNW/ - Three of Synexus' South
African dedicated clinical research centres Stanza, Watermeyer and
Nyeleti have been identified by Pfizer as meeting the exacting
standards that the company demands to join a worldwide network of
INSPIRE sites which must be both highly productive and effective.
INSPIRE, which stands for Investigator Networks, Site Partnerships and
Infrastructure for Research Excellence, means that these sites have
early access to Pfizer's portfolio data and advanced information
regarding the clinical trials to be sponsored by Pfizer. They are also
involved in publications in scientific journals, protocol design,
advisory boards and the sharing of best practice across the INSPIRE
Synexus, which is the world's largest multi-national company focused on
the recruitment and running of clinical trials, already has an INSPIRE
site in Wroclaw Poland.
Tebogo Sebata, Investigator Site Development and Support Lead, Pfizer
Global commented, "We are really delighted that we have been able to
identify these sites and add them to our INSPIRE network. We put in
place the INSPIRE programme so that we can work with the best sites
across the world. Centres which have real expertise in the science of
clinical trials, the infrastructure support that is necessary, proven
recruitment strategies and the in depth knowledge can help us maximize
our development programmes going forward."
Dr Sanet Aspinall, Managing Director of Synexus South Africa, commented,
"We are thrilled to have been invited to become part of the INSPIRE
network. We have had to go through an exhaustive assessment programme
which looked at our previous experience, expertise across a range of
therapeutic areas, infrastructure and resources and effective
recruitment strategies. This is not only excellent for our company but
for South Africa as it shows that it is a very good place in which to
carry out clinical trials."
Dr Glynis Neagle, Chief Medical Officer for Synexus concluded, "We are
really focussed on providing our clients with quality patients and
data. To do this, we are training our doctors and clinical staff in the
medical science of the therapy areas we focus on; cardiovascular,
metabolic (diabetes and obesity), bone, respiratory, infectious
diseases and CNS (dementia and pain). Our investigators are experts in
clinical trials and apply this knowledge to each trial which gives
added value to clients."
For further information:
Simon Vane Percy